Literature DB >> 12937140

A novel role for erythropoietin during fibrin-induced wound-healing response.

Zishan A Haroon1, Khalid Amin, Xiaohong Jiang, Murat O Arcasoy.   

Abstract

In this study, we investigated the role of the hematopoietic cytokine erythropoietin (EPO) during wound healing, the physiological response to tissue injury. We used an in vivo wound-healing assay (fibrin Z-chambers) consisting of fibrin-filled chambers implanted subcutaneously in rats. The fibrin inside the chambers is replaced by granulation tissue consisting of new blood vessels, macrophages and fibroblasts as part of the wound-healing response. Local, exogenous recombinant EPO administration into the fibrin matrix significantly increased granulation tissue formation in a dose-dependent manner. To investigate the physiological role of endogenous EPO during wound healing, we used soluble EPO receptor or anti-EPO monoclonal antibodies to neutralize EPO and observed dose-dependent inhibition of granulation tissue formation, consistent with an important role for EPO in the wound-healing cascade. The ability of recombinant EPO to promote wound healing was associated with a proangiogenic effect during granulation tissue formation. We also found abundant expression of EPO receptor protein in macrophages, cells that play a pivotal role during wound healing. Modulation of wound healing because of administration of recombinant EPO or inhibition of endogenous EPO-EPO receptor correlated with changes in levels of inducible nitric oxide synthase protein in granulation tissue. These data demonstrate a novel function for EPO by providing in vivo evidence for a physiological role during fibrin-induced wound healing.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12937140      PMCID: PMC1868246          DOI: 10.1016/S0002-9440(10)63459-1

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  44 in total

1.  Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial.

Authors:  Robert J Lederman; Farrell O Mendelsohn; R David Anderson; Jorge F Saucedo; Alan N Tenaglia; James B Hermiller; William B Hillegass; Krishna Rocha-Singh; Thomas E Moon; M J Whitehouse; Brian H Annex
Journal:  Lancet       Date:  2002-06-15       Impact factor: 79.321

2.  SU5416 delays wound healing through inhibition of TGF-beta 1 activation.

Authors:  Zishan A Haroon; Khalid Amin; Wilfred Saito; William Wilson; Charles S Greenberg; Mark W Dewhirst
Journal:  Cancer Biol Ther       Date:  2002 Mar-Apr       Impact factor: 4.742

3.  Early wound healing exhibits cytokine surge without evidence of hypoxia.

Authors:  Z A Haroon; J A Raleigh; C S Greenberg; M W Dewhirst
Journal:  Ann Surg       Date:  2000-01       Impact factor: 12.969

4.  Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts.

Authors:  M Ogilvie; X Yu; V Nicolas-Metral; S M Pulido; C Liu; U T Ruegg; C T Noguchi
Journal:  J Biol Chem       Date:  2000-12-15       Impact factor: 5.157

5.  Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing.

Authors:  H F Dvorak; V S Harvey; P Estrella; L F Brown; J McDonagh; A M Dvorak
Journal:  Lab Invest       Date:  1987-12       Impact factor: 5.662

6.  Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades.

Authors:  M Digicaylioglu; S A Lipton
Journal:  Nature       Date:  2001-08-09       Impact factor: 49.962

7.  Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury.

Authors:  M L Brines; P Ghezzi; S Keenan; D Agnello; N C de Lanerolle; C Cerami; L M Itri; A Cerami
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-12       Impact factor: 11.205

Review 8.  Role of nitric oxide in wound repair.

Authors:  Maria B Witte; Adrian Barbul
Journal:  Am J Surg       Date:  2002-04       Impact factor: 2.565

9.  Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury.

Authors:  Anna K Junk; Antonios Mammis; Sean I Savitz; Manjeet Singh; Steven Roth; Samit Malhotra; Pearl S Rosenbaum; Anthony Cerami; Michael Brines; Daniel M Rosenbaum
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-18       Impact factor: 11.205

10.  Functional significance of erythropoietin receptor expression in breast cancer.

Authors:  Murat O Arcasoy; Khalid Amin; Aysen F Karayal; Shu-Chuan Chou; James A Raleigh; Mahesh A Varia; Zishan A Haroon
Journal:  Lab Invest       Date:  2002-07       Impact factor: 5.662

View more
  41 in total

1.  Erythropoietin protects cardiac myocytes against anthracycline-induced apoptosis.

Authors:  Ping Fu; Murat O Arcasoy
Journal:  Biochem Biophys Res Commun       Date:  2007-01-17       Impact factor: 3.575

2.  Macrophages as novel target cells for erythropoietin.

Authors:  Lilach Lifshitz; Galit Tabak; Max Gassmann; Moshe Mittelman; Drorit Neumann
Journal:  Haematologica       Date:  2010-06-30       Impact factor: 9.941

Review 3.  Erythropoietin in stroke therapy: friend or foe.

Authors:  Rhonda Souvenir; Desislava Doycheva; John H Zhang; Jiping Tang
Journal:  Curr Med Chem       Date:  2015       Impact factor: 4.530

Review 4.  Promises and pitfalls in erythopoietin-mediated tissue protection: are nonerythropoietic derivatives a way forward?

Authors:  Carla Cerami Hand; Michael Brines
Journal:  J Investig Med       Date:  2011-10       Impact factor: 2.895

Review 5.  Effects of erythropoietin on the bone microenvironment.

Authors:  S J McGee; A M Havens; Y Shiozawa; Y Jung; R S Taichman
Journal:  Growth Factors       Date:  2011-11-28       Impact factor: 2.511

Review 6.  Current concepts on burn wound conversion-A review of recent advances in understanding the secondary progressions of burns.

Authors:  Ara A Salibian; Angelica Tan Del Rosario; Lucio De Almeida Moura Severo; Long Nguyen; Derek A Banyard; Jason D Toranto; Gregory R D Evans; Alan D Widgerow
Journal:  Burns       Date:  2016-01-17       Impact factor: 2.744

7.  Two-step purification procedure for recombinant human asialoerythropoietin expressed in transgenic plants.

Authors:  Farooqahmed S Kittur; Elena Arthur; Maikhanh Nguyen; Chiu-Yueh Hung; David C Sane; Jiahua Xie
Journal:  Int J Biol Macromol       Date:  2014-10-25       Impact factor: 6.953

8.  Production of therapeutic proteins in algae, analysis of expression of seven human proteins in the chloroplast of Chlamydomonas reinhardtii.

Authors:  Beth A Rasala; Machiko Muto; Philip A Lee; Michal Jager; Rosa M F Cardoso; Craig A Behnke; Peter Kirk; Craig A Hokanson; Roberto Crea; Michael Mendez; Stephen P Mayfield
Journal:  Plant Biotechnol J       Date:  2010-03-07       Impact factor: 9.803

9.  Differential modulation of angiogenesis by erythropoiesis-stimulating agents in a mouse model of ischaemic retinopathy.

Authors:  Carmel M McVicar; Liza M Colhoun; Jodie L Abrahams; Claire L Kitson; Ross Hamilton; Reinhold J Medina; Dash Durga; Tom A Gardiner; Pauline M Rudd; Alan W Stitt
Journal:  PLoS One       Date:  2010-07-29       Impact factor: 3.240

10.  Site-specific qualitative and quantitative analysis of the N- and O-glycoforms in recombinant human erythropoietin.

Authors:  Jing Jiang; Fang Tian; Yun Cai; Xiaohong Qian; Catherine E Costello; Wantao Ying
Journal:  Anal Bioanal Chem       Date:  2014-07-31       Impact factor: 4.142

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.